Navigation Links
University of Houston engineering professor awarded grant to study melanoma treatment
Date:4/26/2013

A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.

Navin Varadarajan, an assistant professor of chemical and biomolecular engineering, received the Stewart Rahr-MRA Young Investigator Award. The grant gives him $225,000 over three years to study a therapy that has helped melanoma patients who aren't responding to any other treatment.

This treatment is a form of immunotherapy, an emerging field of medicine that involves engineering human immune cells to fight specific diseases. In particular, Varadarajan will study adoptive cell therapy (ACT).

ACT involves tumor-infiltrating lymphocytes (TIL), immune system cells that physically enter and then attack malignant tumors. In ACT, these cells are extracted from a patient and amplified in the lab. The stronger modified cells are then re-infused into the patient to facilitate the fight against his or her specific melanoma.

Early clinical trials using ACT to combat melanoma have been promising. Roughly 50 percent of patients have responded to the treatment, with some even going into complete remission.

"Essentially, ACT has become the last hope for survival for patients with melanoma that aren't responding to other conventional therapies," said Varadarajan.

Many other patients, however, don't respond to ACT at all. Understanding this huge gap in outcomes is the central goal of Varadarajan's research. The key to this work is a special polymer slide Varadarajan has developed dubbed the Nano well array. Instead of a flat surface, the slide has tens of thousands of individual chambers, each with a volume of about 50-100 pictoliters. At that size, the chambers are ideal for holding individual cells an incredibly valuable characteristic, said Varadarajan.

"One of the biggest challenges in biological research is studying individual cells. Standard slides are good for examining cell populations but they can't isolate specific cells. What the Nano well array does is shrink the container so that its dimensions are similar to those of a single cell. That lets us achieve single-cell resolution," he said.

In the first stage of this project, Varadarajan will study different sets of modified TIL cells that have not been injected into a patient. His goal will be to identify their specific properties involved in fighting tumors.

He will then take blood samples from ACT patients who have received identical sets of cells. Exposing these blood samples to the Nano well array, Varadarajan will then single out the engineered TIL cells among all the other cells. Notably, most of these TIL cells won't be those that were originally given to patients. Instead, they'll be the descendants of those first cells several generations removed, in fact.

After isolating and identifying these cells, Varadarajan will remove them from the array. He will then clone them by the million and study their cancer-fighting properties, paying special attention to how they have and haven't changed from the original engineered TIL cells. With all that done, he will match up the different cells with patient outcomes, helping to identify which ones have been the most successful in fighting different types of melanomas.

With this knowledge, researchers and physicians developing ACT for melanoma will be able direct their work toward the most promising treatments, hopefully speeding the development of successful new therapies that can even be targeted to individual patients.

"Immunotherapy is at the forefront of cancer treatment and research. In some cases it has actually resulted in complete remission," Varadarajan said. "To help the most people, though, we've got to understand exactly what properties of infused cells are most effective at fighting cancer. This research will help us quickly identify those properties so they can be included in the future rounds of research and clinical trials."

Varadarajan's collaborator/mentor on this project is Laszlo Radvanyi, professor of melanoma medical oncology research at the University of Texas MD Anderson Cancer Center. Additionally, Richard Willson, a chemical and biomolecular engineering professor at UH, will serve as the departmental mentor.

This is the third cancer research grant Varadarajan has won in recent months. He also received funding from the National Institutes of Health and the Cancer Prevention and Research Institute of Texas to conduct two separate studies on different immunotherapy-based treatments for lymphoma and leukemia.


'/>"/>

Contact: Laura Tolley
ljtolley@uh.edu
713-743-0778
University of Houston
Source:Eurekalert

Related biology news :

1. Saint Louis University, University of Toronto biologists help decode turtle genome
2. Wayne State University startup, Advaita, to participate in new Michigan I-Corps program
3. Indiana University associate professor earns APSs Henry Pickering Bowditch Award
4. University of Southern California scientists reveal natural process that blocks viruses
5. University of Houston engineering researchers theories to be tested in space
6. University of Tennessee professors research shows Gulf of Mexico resilient after spill
7. Mercyhurst Universitys new DNA sequencer to accelerate scientific research in region
8. Student named universitys first Lawrence scholar, researching at national laboratory
9. University of Tennessee professor links massive prehistoric bird extinction to human colonization
10. University of Montreal researchers discover how drug prevents aging and cancer progression
11. University of Californias unofficial favorite sea slug poised to make a comeback
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... , ... January 07, 2019 , ... ... and Artificial Intelligence solutions for precision health in oncology and other key therapeutic ... Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare landscape, ...
(Date:1/4/2019)... ... January 02, 2019 , ... ... noteworthy, as the life science tools and service supplier turned 40 in 2018 ... catalog. The catalog features not just part numbers like most catalogs, but rather, ...
(Date:12/27/2018)... ... December 27, 2018 , ... AxioMed ... its new Boston facility, and is now raising growth capital to ramp up ... market share against inferior ball and socket discs. The capital raise is targeted ...
Breaking Biology News(10 mins):
(Date:12/5/2018)... ... December 05, 2018 , ... STRmix™ – sophisticated forensic ... interpret – has been used to convict a Wyoming man of third-degree sexual assault, ... Laboratory used STRmix™ to test for DNA on the couch cushions on which the ...
(Date:11/29/2018)... , ... November 29, 2018 , ... RAGS, today announced ... by Kickstart Seed Fund, with participation from existing investor and board member Jeremy Andrus, ... Smith of Cotopaxi. The additional funding will enable the company to accelerate its growth ...
(Date:11/27/2018)... SANDY SPRINGS, Ga. (PRWEB) , ... November 27, 2018 , ... ... GA, can now visit Dr. Dan Myers’ practice for treatment, with or without a ... of cosmetic procedures and tools, including porcelain veneers, dental implants, bridges and custom crowns. ...
(Date:11/20/2018)... (PRWEB) , ... November 19, 2018 , ... ... pleased to announce the release of the Chinese translation of Best Practices: Recommendations ... 2018, is a practice-changing publication aimed at advancing the science of biobanking to ...
Breaking Biology Technology: